The number of antiviral medicines receiving approval for use in Australia for people with a COVID-19 infection is growing. Some are for use in people who are already in hospital, others can be prescribed to people still in the community who may be at risk of developing more severe symptoms.
Find out more about these and other medicines helping to treat COVID-19 in the pages, resources and links below.
Information about antiviral medicines for COVID-19
Using COVID-19 antiviral medicines where need is greatest
Oral and other antiviral medicines for the treatment of mild COVID-19 are available for treating Australians at high risk of disease progression. This includes in care facilities, health services and remote communities. These articles provide answers to questions prescribers and pharmacists may have when providing care in these settings.
Oral antivirals and sotrovimab for adults with mild-to-moderate COVID-19 who do not require oxygen
At-a-glance information about the three medicines currently recommended for use in the treatment of non-hospitalised adults with mild–moderate COVID-19 infection, who do not require oxygen but are at risk of progressing to severe disease.
The oral antivirals molnupiravir and nirmatrelvir plus ritonavir are both listed on the Pharmaceutical Benefits Scheme (PBS) for use in patients with mild-to-moderate COVID-19 who are at high risk of progressing to severe disease.